pan vegf capture antibody  (R&D Systems)

Journal: The Journal of Physiology

Article Title: Diabetes‐induced microvascular complications at the level of the spinal cord: a contributing factor in diabetic neuropathic pain

doi: 10.1113/JP275067

Figure Lengend Snippet: A , isolated spinal cord endothelial cells demonstrated increased cell death in 50 m m glucose when compared with 50 m m mannitol and 5 m m glucose ( * P < 0.05, *** P < 0.001). VEGF‐A 165 b treatment prevented high glucose‐induced endothelial cell death ( ** P < 0.01). B , IB 4 stained vasculature in the spinal cord of naïve age matched controls was compared with that in ( C ) diabetic + vehicle (arrowheads = vessels smaller than 6 μm) and ( D ) diabetic + VEGFA 165 b. E , there was a significant reduction in total volume of the microvasculature in the spinal cord of the diabetic + vehicle group in addition to ( F ) a reduction in vessel diameter compared with naïve controls ( ** P < 0.01, *** P < 0.001, n = 4 per group). E and F , VEGF‐A 165 b treatment prevented the diabetes‐induced vascular degeneration in the lumbar spinal cord ( ** P < 0.01, n = 4 per group). G , VEGF‐A 165 b treatment also prevents the diabetes‐induced decrease in larger and intermediate microvessels. Scale bar: B–D = 25 μm. [Color figure can be viewed at http://wileyonlinelibrary.com ]

Article Snippet: Primary antibodies, mouse anti‐CD31 (2 μg ml −1 , Abcam; AB24590), rabbit anti‐occludin (5 μg ml −1 , Invitrogen; 71‐1500), mouse anti‐VE cadherin (5 μg ml −1 , BD Biosciences, Franklin Lakes, NJ, USA; 550548), rabbit anti‐VEGFR2 (1:200, 55B11, Cell Signaling), rabbit anti‐Pan VEGF‐A (A20, 1 μg ml −1 , Santa Cruz; sc‐152), mouse anti‐VEGF‐A 165 b (2 μg ml −1 , Abcam; ab‐14994), and rabbit anti‐Actin (1:100, Santa Cruz) antibodies were diluted in blocking solution and incubated overnight at 4°C.

Techniques: Isolation, Staining

Journal: Scientific Reports

Article Title: Genome-wide expression differences in anti- Vegf and dexamethasone treatment of inflammatory angiogenesis in the rat cornea

doi: 10.1038/s41598-017-07129-4

Figure Lengend Snippet: Limbal vessel dilation, inflammatory cell infiltration and Vegfa expression following IgG, anti- Vegf and dexamethasone treatment of suture-induced injury in the rat cornea. ( A ) Slit lamp photographs depicting limbal vessel dilation and looping angiogenesis 48 h after suture placement in IgG and anti- Vegf groups, not detected in the dexamethasone group; expanded view of the white boxed area in ( B ). ( C ) IVCM images of limbal vessel dilation, and the corresponding measurements of limbal vessel diameter in ( G ); ( D ) Microscopic images of aqueous humor cellular content, and the corresponding quantification in ( H ). ( E ) Immunofluorescence of Vegfa (green) and DAPI counterstaining of nuclei (blue) in corneal tissue sections. ( F ) CD31 staining (green) of naïve and sutured cornea at 48 hours: the latter shows no sign of corneal neovascularization. n = 4 corneas per group for ( G) and ( H) , *P < 0.05; **P < 0.01; ***P < 0.001; n.s. = P > 0.05 and error bars represent SD.

Article Snippet: The time of suture placement was designated as 0 h. Sutured animals were randomly assigned to one of three topical treatment groups: Rat-specific goat polyclonal pan- Vegf antibody (20 μg/ml, Cat. No AF 564, R&D Systems, Minneapolis MN, USA).

Techniques: Expressing, Immunofluorescence, Staining

Journal: Scientific Reports

Article Title: Genome-wide expression differences in anti- Vegf and dexamethasone treatment of inflammatory angiogenesis in the rat cornea

doi: 10.1038/s41598-017-07129-4

Figure Lengend Snippet: Differentially expressed genes (DEGs) in IgG, dexamethasone and anti- Vegf treated groups, and selected enriched biological processes. ( A–C) Volcano plots of the DEGs in IgG, dexamethasone and anti- Vegf groups respectively. (D) Selected biological processes of interest, indicating the number of DEGs involved in the processes for each treatment.

Article Snippet: The time of suture placement was designated as 0 h. Sutured animals were randomly assigned to one of three topical treatment groups: Rat-specific goat polyclonal pan- Vegf antibody (20 μg/ml, Cat. No AF 564, R&D Systems, Minneapolis MN, USA).

Techniques:

Journal: Scientific Reports

Article Title: Genome-wide expression differences in anti- Vegf and dexamethasone treatment of inflammatory angiogenesis in the rat cornea

doi: 10.1038/s41598-017-07129-4

Figure Lengend Snippet: The top 10 differentially up- and downregulated genes involved in selected biological processes (a), and in selected pathways (b).

Article Snippet: The time of suture placement was designated as 0 h. Sutured animals were randomly assigned to one of three topical treatment groups: Rat-specific goat polyclonal pan- Vegf antibody (20 μg/ml, Cat. No AF 564, R&D Systems, Minneapolis MN, USA).

Techniques:

Journal: Scientific Reports

Article Title: Genome-wide expression differences in anti- Vegf and dexamethasone treatment of inflammatory angiogenesis in the rat cornea

doi: 10.1038/s41598-017-07129-4

Figure Lengend Snippet: Pathway enrichment analysis indicates that dexamethasone suppresses most DEGs in all selected inflammatory and angiogenesis pathways, relative to IgG and anti- Vegf treatment.

Article Snippet: The time of suture placement was designated as 0 h. Sutured animals were randomly assigned to one of three topical treatment groups: Rat-specific goat polyclonal pan- Vegf antibody (20 μg/ml, Cat. No AF 564, R&D Systems, Minneapolis MN, USA).

Techniques:

Journal: Scientific Reports

Article Title: Genome-wide expression differences in anti- Vegf and dexamethasone treatment of inflammatory angiogenesis in the rat cornea

doi: 10.1038/s41598-017-07129-4

Figure Lengend Snippet: ( A–G ): Immunofluorescent staining of naïve, and sutured corneas from treatment groups (48 h post-suture). Factors most differentially regulated between dexamethasone and anti- Vegf groups from microarray analysis are shown. Expression signals are indicated in green, and DAPI counterstained nuclei in blue. Scale bar = 50 µm. ( H–J ): qPCR analysis of C3 , C1s and Vegfa gene expression. The error bars represent SEM.

Article Snippet: The time of suture placement was designated as 0 h. Sutured animals were randomly assigned to one of three topical treatment groups: Rat-specific goat polyclonal pan- Vegf antibody (20 μg/ml, Cat. No AF 564, R&D Systems, Minneapolis MN, USA).

Techniques: Staining, Microarray, Expressing, Gene Expression

Journal: Scientific Reports

Article Title: Genome-wide expression differences in anti- Vegf and dexamethasone treatment of inflammatory angiogenesis in the rat cornea

doi: 10.1038/s41598-017-07129-4

Figure Lengend Snippet: Summary of genes involved in the complement cascade from gene microarray analysis, and the FC Diff and the corresponding P values.

Article Snippet: The time of suture placement was designated as 0 h. Sutured animals were randomly assigned to one of three topical treatment groups: Rat-specific goat polyclonal pan- Vegf antibody (20 μg/ml, Cat. No AF 564, R&D Systems, Minneapolis MN, USA).

Techniques: Microarray, Binding Assay, Virus

Journal: Scientific Reports

Article Title: Genome-wide expression differences in anti- Vegf and dexamethasone treatment of inflammatory angiogenesis in the rat cornea

doi: 10.1038/s41598-017-07129-4

Figure Lengend Snippet: Summary of complement genes differentially regulated by dexamethasone treatment relative to anti- Vegf , and their roles in the complement cascade based on gene expression microarray analysis. Differentially regulated genes (upregulated genes labelled in red, downregulated genes in green) are shown along with their fold change difference (dexamethasone minus anti- Vegf ) and corresponding p-value (between dexamethasone and anti- Vegf fold change) given in parentheses. All differentially regulated genes mapped to the classical pathway, while Cfi , a natural inhibitor of C3 and C5 convertase production, was strongly downregulated. This, combined with strong upregulation of C3 , promoted pathways leading to inflammatory cell activation and invasion into the cornea following dexamethasone treatment. Further downstream complement components ( C6 – C9 ) leading to cell lysis were not differentially regulated by dexamethasone. The figure is an adapted version of the conceptual diagram presented by del Zoppo .

Article Snippet: The time of suture placement was designated as 0 h. Sutured animals were randomly assigned to one of three topical treatment groups: Rat-specific goat polyclonal pan- Vegf antibody (20 μg/ml, Cat. No AF 564, R&D Systems, Minneapolis MN, USA).

Techniques: Gene Expression, Microarray, Activation Assay, Lysis

Journal: Proceedings of the National Academy of Sciences of the United States of America

Article Title: Mechanisms regulating angiogenesis underlie seasonal control of pituitary function

doi: 10.1073/pnas.1618917114

Figure Lengend Snippet: Primary antibodies

Article Snippet: Pan VEGF-A , Against all isoforms of human VEGF-A (A20) , Rabbit polyclonal , Santa Cruz Biotechnology; sc-152 , 200 μg/mL diluted 1:100.

Techniques: Produced, Recombinant, Concentration Assay, Marker